The Role of Baff and Baff-R Inhibitors in the Treatment of Immune Thrombocytopenia; a Focused Review Publisher Pubmed



Nilforoushzadeh MA^{1, 2} ; Heidari N^{1, 2, 3} ; Heidari A^{1, 2, 4} ; Ghane Y^{1, 2, 5} ; Lotfi Z¹ ; Jaffary F^{1, 2} ; Najar Nobari M⁶ ; Najar Nobari N^{1, 2, 7}
Source: International Immunopharmacology Published:2024

Abstract

Immune thrombocytopenia (ITP) is an autoimmune-driven disease characterized by increased destruction and impaired platelet production resulting in an enhanced risk of bleeding. Immunosuppressant agents are the most common treatment strategies for ITP. Despite their efficacy, these medications often cause unpredictable side effects. Recent investigations revealed that patients with ITP exhibit elevated B-cell activating factor (BAFF) levels in both their spleens and serum. Belimumab, a BAFF inhibitor, illustrated a promising therapeutic avenue for managing ITP by interfering with BAFF activity and long-lived plasma cell production. Both clinical and experimental studies have yielded positive outcomes when combining rituximab with an anti-BAFF monoclonal antibody in treating ITP. In addition, ianalumab, a monoclonal antibody with a dual mechanism that targets BAFF-R and deletes peripheral BAFF-R+ B cells, is currently being used for ITP treatment [NCT05885555]. The upcoming results from novel BAFF inhibitors, such as ianalumab, could offer clinicians an additional therapeutic option for treating ITP. © 2024